Research programme: fibroblast growth factor receptor inhibitors - Exelixis
Latest Information Update: 10 Mar 2011
At a glance
- Originator Exelixis
- Class Small molecules
- Mechanism of Action Fibroblast growth factor receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer